221 studies found for:    "Meningococcal infection"
Show Display Options
Rank Status Study
1 Completed Creation of a Biotheque of Patients of Seine-Maritime With Meningococcal Infection
Condition: Meningococcal Infections
Intervention:
2 Active, not recruiting Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)
Condition: Meningococcal Infections
Intervention: Biological: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
3 Completed Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age
Condition: Meningococcal Infection
Intervention: Biological: Meningococcal C conjugate vaccine
4 Completed
Has Results
Immunogenicity of the Booster Dose of Two MenC Vaccines
Condition: Meningococcal Infection
Intervention: Biological: conjugated polysaccharide menC vaccine
5 Completed
Has Results
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules
Condition: Meningococcal Infections
Interventions: Biological: rMenB+OMV NZ;   Biological: combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine;   Biological: Pneumococcal vaccine
6 Completed Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers
Condition: Meningococcal Infection
Interventions: Biological: Meningococcal vaccine GSK 134612;   Biological: SynflorixTM;   Biological: Infanrix-IPV/HiberixTM
7 Completed
Has Results
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM + MMRV;   Biological: MMRV;   Biological: MenACWY-CRM
8 Completed
Has Results
Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children
Condition: Meningococcal Infections
Interventions: Biological: MenACWY-CRM;   Biological: Licensed meningococcal ACWY vaccine
9 Active, not recruiting A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
Condition: MENINGOCOCCAL INFECTION
Interventions: Biological: Bivalent rLP2086 Vaccine;   Biological: Licensed pediatric hepatits A vaccine;   Other: Normal Saline
10 Recruiting Duration of Immunity Study
Condition: Meningococcal Infection
Interventions: Procedure: blood sampling;   Drug: bivalent rLP2086
11 Active, not recruiting Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization
Condition: Meningococcal Infections
Interventions: Biological: 4CMenb;   Biological: diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB;   Biological: conjugated pneumococcal vaccine;   Biological: MMRV
12 Completed Regulation of Mucosal Immune Response to Systemic MenB Vaccine
Condition: Meningococcal Infections
Intervention: Biological: NZ MenB OMV vaccine (NZ98/254)
13 Terminated B14 Meningococcal Carriage in Seine-Maritime Population: Prevalence Study and Search of Risk Factors
Condition: Meningococcal Infections
Intervention:
14 Completed Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects
Condition: Meningococcal Disease
Intervention: Biological: rMenB+OMV
15 Active, not recruiting MenPF-1 - A New Vaccine Against Meningococcal Disease
Condition: Serogroup B Meningococcal Disease
Intervention: Biological: MenPF-1.
16 Completed Group B Meningococcal Vaccine
Condition: Meningococcal Infection, Group B
Intervention: Biological: Group B Meningococcal 8570 HOPS-G NOMV Vaccine
17 Completed Persistence of Antibody Response to N. Meningitidis Group C in Children
Condition: Prevention of Meningococcal Infection
Intervention: Biological: Meningococcal C conjugate vaccine
18 Completed Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children
Condition: Prevention of Meningococcal Infection
Intervention: Biological: Meningococcal C conjugate vaccine
19 Completed Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine
Condition: Prevention of Meningococcal Infection
Intervention: Biological: Meningococcal C conjugate vaccine
20 Completed Kinetics of B Cell Response in Infants Menjugate Vaccination
Condition: Prevention of Meningococcal Infection
Intervention: Biological: Meningococcal C conjugate vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.